|Title:||Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response||Authors:||CHUN-MING HONG
|Keywords:||direct-acting antivirals; hepatitis C; resistance-associated variant||Issue Date:||Apr-2017||Publisher:||ELSEVIER TAIWAN||Journal Volume:||116||Journal Issue:||4||Start page/Pages:||295||Source:||Journal of the Formosan Medical Association = Taiwan yi zhi||Abstract:||
Daclatasvir is a nonstructural protein 5A inhibitor with potent activity against hepatitis C virus genotypes 1-6 in vitro, and asunaprevir is a nonstructural protein 3 protease inhibitor with activity against genotypes 1, 4, 5, and 6. Despite a 90% sustained virologic response (SVR) rate, the SVR rate in patients with baseline NS5A-L31/Y93H polymorphisms decreased to around 40%. Therefore, an alternative regimen under the consideration of cost-effectiveness would be important. Whether the addition of ribavirin could improve the SVR rate among this group of patients remains unknown and hence our case series was reported.
|Appears in Collections:||微生物學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.